HAIC enhances treatment outcomes for advanced hepatocellular carcinoma

A meta-analysis involving 1,244 patients found that hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and PD-1 inhibitors significantly improved overall survival (OS) and progression-free survival (PFS) compared to lenvatinib with PD-1 inhibitors alone. Specifically, this combination led to a hazard ratio of 2.11 for OS and 1.91 for PFS. Additionally, the objective response rate (ORR) and disease control rate (DCR) also increased. Extrahepatic metastasis emerged as a significant negative prognostic factor.